Zinc stable isotopes in urine as diagnostic for cancer of secretory organs
Autor: | Alex N. Halliday, Lois Vesty-Edwards, Kate Goddard, Kathrin Schilling, Miles S. Capper, Fiona Larner, R. Charles Coombes, Alastair D. Lamb, Charlotte Ion, Kaj Sullivan, Rebekah E. T. Moore, Mark Rehkämper |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male medicine.medical_specialty diagnosis Urinary system Biophysics Breast Neoplasms Urine 01 natural sciences Biochemistry Gastroenterology secretory organs Analytical Chemistry Biomaterials 03 medical and health sciences Prostate cancer Young Adult Breast cancer Prostate Internal medicine Pancreatic cancer Biomarkers Tumor cancer Medicine Humans Zn stable isotopes 030304 developmental biology 0303 health sciences business.industry 010401 analytical chemistry Metals and Alloys Cancer Prostatic Neoplasms Middle Aged medicine.disease Prognosis urine 0104 chemical sciences Pancreatic Neoplasms medicine.anatomical_structure dyshomeostasis Chemistry (miscellaneous) Case-Control Studies Female Zinc Isotopes Breast disease 03 Chemical Sciences business |
Zdroj: | Metallomics : integrated biometal science. 13(5) |
ISSN: | 1756-591X |
Popis: | Breast, prostate, and pancreatic cancers alter the zinc (Zn) metabolism. Combined analyses of urinary Zn concentrations [Zn] and Zn stable isotope compositions (δ66Zn) may provide a non-invasive approach for tracing malignancy-induced Zn dyshomeostasis. In this study, we measured [Zn] and δ66Zn in urine from prostate (n = 22), breast (n = 16), and from women with benign breast disease (n = 14) and compared those with age-matched healthy controls (22–49 years or 50+ years) and published data for pancreatic cancer (n = 17). Our results show that cancer-induced changes are reflected in higher urinary [Zn] and lower urinary δ66Zn for pancreatic and prostate cancer and benign breast disease when compared with healthy controls. For prostate cancer, the progression of low [Zn] and high δ66Zn for patients of low-risk disease toward high [Zn] and low δ66Zn for the higher risk patients demonstrates that [Zn] and δ66Zn in urine could serve as a reliable prognostic tool. Urinary excretion of isotopically light Zn by patients with prostatic and pancreatic cancer is probably the result of increased reactive oxygen species in cancerous cells, which limits the scavenging of hydroxyl radicals and thus facilitates the oxidation of metalloproteins with sulfur-rich ligands. Urine from breast cancer patients shows undistinguishable δ66Zn to healthy controls, implying that the expression of metalloproteins with sulfur-rich ligands is stronger in breast cancer tissues. In conclusion, urinary δ66Zn may provide a non-invasive diagnostic tool for pancreatic cancer and support disease prognosis for prostate cancer. These findings should translate to comprehensive transverse and longitudinal cohort studies in future. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...